Physician profile
Michael Mull
NPI 1194225342
$9,803.06
in general payments reported to CMS, 2019-2025
32 companies · $539 in 2025
The $539 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $5,081 · 2022: $3,132 · 2023: $506 · 2024: $545 · 2025: $539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,558 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,558.05 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,044.45 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Sanofi-Aventis U.S. LLC | $1,081.79 | 2021-2025 | |
| Lilly USA, LLC | $1,069.10 | 2021-2024 | Mounjaro |
| Astrazeneca Pharmaceuticals Lp | $712.05 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $605.21 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $601.23 | 2021-2022 | |
| Amneal Pharmaceuticals LLC | $527.56 | 2021-2022 | |
| Dexcom, INC. | $522.54 | 2023-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Amgen INC. | $379.26 | 2021-2025 | Evenity |
| Abbvie INC. | $308.68 | 2021-2022 | |
| Abbott Laboratories | $260.05 | 2021-2022 | |
| Becton, Dickinson and Company | $257.69 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $246.33 | 2021-2022 | |
| Zealand Pharma US, INC. | $166.23 | 2022 | |
| Tandem Diabetes Care, INC. | $165.52 | 2021-2023 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $164.48 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $145.92 | 2021 | |
| Corcept Therapeutics | $81.62 | 2021-2022 | |
| Embecta Corp. | $64.69 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Xeris Pharmaceuticals, INC. | $63.69 | 2021-2022 | |
| Esperion Therapeutics, INC. | $51.91 | 2021 | |
| Novartis Pharmaceuticals Corporation | $50.24 | 2022 | |
| Alexion Pharmaceuticals, INC. | $49.51 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $39.46 | 2021 | |
| Ibsa Pharma INC. | $37.54 | 2021 | |
| Mannkind Corporation | $18.10 | 2021 | |
| Vivus LLC | $17.95 | 2021 | |
| Nevro Corp. | $16.70 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $15.66 | 2021 | |
| Acerus Pharmaceuticals Corporation | $12.96 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $12.93 | 2022 | |
| Insulet Corporation | $12.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mull listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.